Gapping up
In reaction to strong earnings/guidance: ATEN +17.8%,
IM +16.3%,
NLS +16.2%,
ABMD +15.1%,
ELNK +12.4%,
CHUY +11.7%,
ECOM +9.8%, (also Names David Spitz Chief Executive Officer and Scot Wingo Executive Chairman),
AMRI +7.4%,
UBS +7.1%,
EFOI +7.1%,
NLNK +7%,
SSE +6.7%,
CRTO +5.8%,
TXRH +5.3%,
MERU +4.5%,
EL +4.5%,
MNK +4.4%,
DENN +4.1%,
ININ +4.1%,
NUVA +3.8%,
TCPI +3.7%,
LMNX +3.6%,
CYNO +3.5%,
CKEC +3.2%,
CTT +3.1%,
MATX +3%,
SALE +2.9%,
THC +2.1%,
IDTI +2.1%,
CGNX +1.9%,
AEGR +1.8%,
HCP +1.8%,
BLMN +1.7%,
OZM +1.5%,
ZTS +1.4%,
DISCA +1.4%,
DISCA +1.4%,
LPX +1.2%,
GTN +1.1%,
H +1.1%,
VMC +1%,
CDE +0.9%,
ALLT +0.9%,
APC +0.8%,
PLOW +0.8%,
PCOM +0.8%,
NTI +0.8%,
HW +0.8%,
AFSI +0.8%
Select oil/gas related names showing strength with WTI up ~2% pre-mkt: EXXI +5.7%,
OAS +2.2%,
SDRL +1.9%,
RIG +1.7%,
XOM +0.8%,
CVX +0.8%
Other news: PTBI +45.1% (Soros Fund Management disclosed 5.17% passive stake in 13G filing),
GLNG +17.1% (Ophir Energy plc appoints Golar as midstream partner for Fortuna FLNG project in Equatorial Guinea),
ECOM +9.8% (named David Spitz CEO and Scot Wingo Executive Chairman effective today; co also reported earnings),
JAH +4.4% (following yesterday's positive mention by Pershing Square's Ackman),
ISIS +3.4% (favorably commentary on Monday's Mad Money),
ZIOP +2.4% (announces the initiation of a Phase 1 study of Ad-RTS-hIL-12 plus veledimex),
BCO +2.1% ( Starboard Value discloses 8.2% active stake in 13D filing),
ARWR +2% (announced that it completed dosing volunteers and will begin dosing patients in its on-going Phase 1 study of ARC-AAT),
BNFT +1.8% (announced the signing of a reseller agreement with SAP),
ISSI +1.6% (Starboard Value increased active stake to 11.5% from 9.9% in amended 13D filing)
Analyst comments: CONN +8% (upgraded to Outperform from Perform at Oppenheimer),
TSLA +3.5% (initiated with a Buy at Jefferies; tgt $350),
NFLX +2.2% (upgraded to Buy at BofA/Merrill),
ALU +2.1% (upgraded to Buy from Neutral at Citigroup),
ASEI +2.1% (upgraded to Buy at The Benchmark Company),
SAFM +1.9% (upgraded to Overweight from Equal Weight at a boutique firm),
ARRS +1.8% (upgraded to Buy from Neutral at Goldman),
CYNI +1.7% (upgraded to Neutral from Underweight at JP Morgan),
JBLU +1.4% (upgraded to Overweight from Neutral at JP Morgan),
ETN +1.2% (upgraded to Overweight from Neutral at JP Morgan)